Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...

Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

UBS analyst Colin Bristow downgraded Applied Therapeutics (APLT) to Neutral from Buy with a price target of $2, down from $13.Don't Miss our ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.

Shares of Applied Therapeutics (APLT) plummeted 76.3% after the FDA rejected approval for its drug intended to treat a rare genetic metabolic disorder. Target Corporation’s (TGT) shares jumped 1.7% on ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75 ...

Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective lowered by Citigroup from $13.00 to $8.00 in a ...

Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective reduced by Robert W. Baird from $14.00 to $5.00 in a ...

The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.

Applied Therapeutics ( APLT, Financials) announced that the U.S. Food and Drug Administration issued a Complete Response ...

Fintel reports that on November 29, 2024, RBC Capital downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from ...

Baird lowered the firm’s price target on Applied Therapeutics (APLT) to $5 from $14 and keeps an Outperform rating on the shaes. The firm ...